Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial
PLOS One · 17.06.2025 · 20 (6) · e0319319
DOI: 10.1371/journal.pone.0319319 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 17.06.2025. Verfasst von Naoki Suzuki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Data science, Tojinkai Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Hyperphosphatemia, Constipation, Renal Dialysis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Tenapanor is a minimally absorbed, small-molecule inhibitor of sodium/hydrogen exchanger 3 and thus suppresses sodium absorption in the gastrointestinal tract. It is approved by the FDA for the treatment of hyperphosphatemia in dialysis patients. This randomized controlled trial evaluated its efficacy in the treatment of hyperphosphatemia and constipation in hemodialysis patients.
Methods
Ninety hemodialysis patients were randomized 1:1 to receive either tenapanor or standard care. Randomization was performed using a computer-generated sequence stratified by baseline serum phosphorus levels. The tenapanor group began treatment with a dosage of 10 mg/day, which was adjusted based on serum phosphorus levels. Primary outcomes were changes in serum phosphorus levels in the tenapanor and control groups and changes in stool consistency, assessed weekly using the Bristol Stool Form Scale (BSFS) in the tenapanor group. Secondary outcomes included laxative use and phosphate binder prescription patterns. Serum phosphorus levels, serum calcium, albumin, and related biochemical parameters were monitored every two weeks. Data were analyzed using intention-to-treat principles. This study was not blinded.
Results
Of the 90 randomized participants, 69 completed the 23-week study. Tenapanor significantly improved stool consistency and resolved constipation (BSFS types 1–2) by week 5. A transient increase in loose stools (BSFS types 6–7) occurred early, with 10 participants discontinuing due to diarrhea. Laxative use decreased significantly in the tenapanor group, from 58.2% at baseline to 35.6% at week 23 (p < 0.01). Serum phosphorus levels were decreased in both groups, with comparable control. Lanthanum carbonate prescriptions decreased significantly in the tenapanor group and were largely replaced by low-dose tenapanor.
Conclusion
Tenapanor improves stool consistency, reduces laxative use, and provides effective phosphorus control in hemodialysis patients and represents a promising alternative to conventional phosphate binders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Data science, Tojinkai Hospital, Kyoto, Japan.
- Division of Clinical Engineering, Tojinkai Hospital, Kyoto, Japan.
- Nephrology Division, Tojinkai Satellite Clinic, Kyoto, Japan.
- Cardiovascular Division, Tojinkai Satellite Clinic, Kyoto, Japan.
- Urology Division, Tojinkai Hospital, Kyoto, Japan.
ORCID-Profile: Naoki Suzuki, Yasumasa Hitomi
Zitieren
APA
Suzuki, N., Takeda, Y., Kabuto, A., Konishi, T., Konishi, T., Sumino, F., Iwata, H., Iwagami, M., Kouchi, Y., Hitomi, Y., Takatani, T., Nishimura, M., & Sato, N. (2025). Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial. PLOS One, 20(6), e0319319. https://doi.org/10.1371/journal.pone.0319319
Vancouver
Suzuki N, Takeda Y, Kabuto A, Konishi T, Konishi T, Sumino F, et al. Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial. PLOS One. 2025;20(6):e0319319. doi:10.1371/journal.pone.0319319
BibTeX
@article{Suzuki2025,
author = {Suzuki, Naoki and Takeda, Yuuki and Kabuto, Akie and Konishi, Takao and Konishi, Takahiro and Sumino, Fumi and Iwata, Hayanari and Iwagami, Mone and Kouchi, Yusuke and Hitomi, Yasumasa and Takatani, Toru and Nishimura, Masato and Sato, Nodoka},
title = {Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {6},
pages = {e0319319},
doi = {10.1371/journal.pone.0319319}
}
EUVIMED